Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.
Purity:
95.00%
CAS Number:
[1491917-83-9]
T77824
* VAT and and shipping costs not included. Errors and price changes excepted